Home � Products & Services � Benchmarking Reports � Medical Affairs � Field Medical Excellence

Enhancing MSL Interactions with Non-US Healthcare Practitioners

Download FREE Excerpt

ID: POP-304

Features:

3 Info Graphics

12 Data Graphics

100 Metrics

6 Narratives

Pages: 22

Published: 2019

Delivery Format: Shipped

License Options:
$1300 - 1 user
$3900 - Up to 5 users
$6500 - Up to 20 users

Buy Now

919-403-0251

Schedule a Meeting

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

Globally, pharmaceutical field medical specialists such as Medical Science Liaisons (MSLs) serve as a key conduit between pharma and healthcare practitioners (HCPs). However, field team interaction practices differ markedly when comparing US and the regions outside United States.

MSL interactions with non-US HCPs continues to evolve as pharmaceutical companies are re-evaluating and updating their guidelines for scientific interactions.

Best Practices, LLC conducted this benchmarking research to gather insights on current MSL practices for HCP interactions outside the US. This report establishes benchmarks around HCP interactions and proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. This report also delivers insights on the frequency, format, content and evaluators for recertification of MSLs.

Global or non-US pharmaceutical field medical team leadership can refer to this research to compare their approach to MSL interactions with current industry practices.

Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories

Companies Profiled:
Alfasigma; Allergan; Bayer; Boehringer Ingelheim; Janssen; Merck; Pfizer; Sanofi; Vifor Pharma

Study Snapshot

Best Practices, LLC engaged nine medical affairs leaders based outside the US from 9 leading biopharmaceutical companies in this research through a benchmarking survey. Fifty-six percent of the respondents serve at the Director level; and 22% serve as Heads.

Key topics covered in this report include:

MSL Interactions with HCP Groups
MSL Involvement in Proactive Disease State Education
MSL Engagement with KOLs in Early Development Stage
Best Practices for MSL Interactions Outside the US
Re-certification of MSLs

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

Proactive Disease State Education: MSLs outside the US typically do proactive disease state education 1 year prior to launch; 33% of respondents have no restrictions on timing for presentations.
Off-Label Exchanges: Forty-four percent of participants allow off-label exchanges after an unsolicited request and another 22% allow it if requested by HCPs. The remaining 33% do not allow.

Table of Contents

1.	Executive Summary	pgs. 3-7
	Benchmark Class
	MSL Interactions Overview
2.	MSL Interactions with Non-US HCPs	pgs. 8-13
3.	MSL Involvement in Proactive Disease State Education	pg. 14
4.	MSL Engagement with KOLs in Early Development Stage	pg. 15
5.	Best Practices for MSL Interactions	pg. 16
6.	Recertification of MSLs	pgs. 17-18
	Format for Testing
	Subject Matter/ Content for Testing
	Evaluators for Recertification Testing
7.	Appendix	pgs. 19-21

List of Charts & Exhibits

I. MSL Interactions with Non-US HCPs

Permission given to MSLs to present standard of care treatment information in proactive disease presentation
Permission given to MSLs to leave behind slides from a disease state presentation on an HCP’s request
Permission given to MSLs to present clinical data on an unapproved product upon receiving an unsolicited request
Permission given to MSLs to present off-label clinical information of an approved product in a group HCP setting, upon receiving an unsolicited request
Permission given to MSLs to respond to off-label questions during a presentation in a group HCP setting
Development stage at which MSLs are allowed to do proactive disease state (non-product) education
Timing of MSL engagement of KOLs in the development process
Best practices for MSL interactions with non-US HCPs

II. MSL Recertification

Frequency, format, content and evaluators for recertification of MSLs